Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Shares of Novavax Inc surged nearly 20% on Wednesday after advisers to the Food and Drug Administration overwhelmingly backed the use of its COVID-19 vaccine, bringing the shot a step closer to a U.S. launch.

Novavax shares jump as FDA panel backs COVID vaccine

The Food and Drug Administration's vaccines advisory panel backed Novavax 's long-delayed Covid-19 vaccine, saying the benefits outweighed the risks.

FDA Advisors Back Novavax's Covid Shot, Clearing Way for Authorization

Novavax, Inc. (NASDAQ:NVAX) said its Covid-19 vaccine has been recommended for approval by the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee.  The committee voted to recommend Emergency Use Authorization (EUA) for the Novavax Covid-19 vaccine (NVX-CoV2373) for people aged 18 years and over, the biotechnology company said in a statement.

Novavax Covid-19 vaccine recommended for US approval by FDA advisory panel

The FDA itself still needs to authorize the two-dose series.

FDA Panel Endorses Novavax, a Fourth COVID Vaccine

Novavax COVID-19 vaccine receives positive vote from U.S. Food and Drug Administration Vaccines and Related Biological Products Advisory Committee If Emergency Use Authorization is granted by the FDA, the Novavax COVID-19 vaccine would become the first protein-based COVID-19 vaccine available in the U.S. GAITHERSBURG, Md. , June 7, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the U.S. Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 21 to 0, with one abstention, to recommend that the FDA grant Emergency Use Authorization (EUA) for the Novavax COVID-19 vaccine (NVX-CoV2373) for individuals aged 18 years and over.

FDA Advisory Committee Recommends Emergency Use Authorization of Novavax COVID-19 Vaccine for People Aged 18 Years and Older

The FDA typically follows the panel's recommendations for approval, which would make the shot the fourth FDA-authorized Covid-19 vaccine for adults.

FDA Advisory Panel Endorses Novavax—1st Protein-Based Covid Vaccine

American adults who haven't yet gotten vaccinated against COVID-19 may soon get another choice, as advisers to the Food and Drug Administration on Tuesday backed a more traditional type of shot.

FDA advisory committee recommends Novavax's COVID-19 vaccine for use

Novavax Inc (NASDAQ: NVAX) shares have been halted since the pre-market session as the U.S. Food and Drug Administration holds a meeting to determine the fate of the company's COVID-19 vaccine. A committee of independent FDA vaccination advisors have been .

What's Going On With Novavax Stock Today?

The Food and Drug Administration's advisory committee voted unanimously to recommend Novavax's Covid-19 vaccine for use in the U.S.

Novavax Covid vaccine clears key step on path to FDA authorization after committee endorses the shot

A Food and Drug Administration (FDA) advisory committee is meeting on Tuesday to discuss a request for emergency use authorization (EUA) for Novavax COVID vaccines.

COVID vaccines: FDA to meet over Novavax

Novavax (NVAX) stock is in the news today as investors prepare for the results from the vaccine company's meeting with the FDA. The post NVAX Stock Alert: 14 Things to Know as the Novavax Vaccine Faces the FDA Today appeared first on InvestorPlace.

NVAX Stock Alert: 14 Things to Know as the Novavax Vaccine Faces the FDA Today

An advisory panel to the U.S. Food and Drug Administration is meeting Tuesday to review the vaccine developed by Novavax Inc. as a potential fourth shot for American adults and will vote on whether the risks outweigh the benefits.

Coronavirus Update: FDA panel set to review protein-based Novavax vaccine

A federal advisory panel is set to vote on Tuesday on whether the FDA should authorize the company's Covid shot.

Novavax Stock Halted Pending FDA Panel Meeting—Here's What To Know About The Company's Covid Vaccine

Vaxart

Both face significant risks in the coming quarters.

Better Buy: Novavax vs. Vaxart

An FDA advisory committee is holding a meeting Tuesday on whether to approve Novavax's Covid-19 vaccine.

Novavax Stock Halted Ahead of FDA Advisory Panel Hearing on Covid Vaccine

Clinical trials found the vaccine to work well, but the company has long struggled with manufacturing.

F.D.A. Advisers To Weigh In On Covid Shots by Novavax

The good news from a set of FDA briefing documents ultimately outweighed the bad news.

Why Novavax Stock Dipped, Then Soared, on Monday

Before deciding the fate of Novavax's (NVAX) COVID-19 vaccine, a document issued by the FDA suggests that the vaccine may cause heart problems like myocarditis/pericarditis.

Novavax (NVAX) Down After FDA Raises Concern for Its COVID Jab

The Food and Drug Administration's independent experts will review the safety and effectiveness of Novavax's Covid vaccine Tuesday.

Novavax faces high stakes FDA review this week that will decide the fate of its Covid vaccine in the U.S.

Novavax (NVAX) stock is falling on Friday after the FDA requested a heart inflammation warning for the company's Covid-19 vaccine. The post Novavax (NVAX) Stock Falls 25% on FDA Heart Inflammation Warning appeared first on InvestorPlace.

Novavax (NVAX) Stock Falls 25% on FDA Heart Inflammation Warning

Shares of Novavax Inc. NVAX, -23.74% tumbled 22.9% in trading on Friday after the Food and Drug Administration published a report that detailed the agency's assessment of the clinical data for the company's COVID-19 vaccine candidate. There were at least four instances of myocarditis, a type of heart inflammation, in the clinical-trial participants.

Novavax's stock slides 23% after FDA details myocarditis cases for COVID-19 vaccine candidate

'Multiple events' of heart inflammation were reported after administering the Covid-19 vaccine, especially among younger men, according to the FDA.

Novavax Covid-19 Vaccine Linked to Heart Inflammation, FDA Says. The Stock Is Sliding.

Shopify

Should you buy these incredibly steep dips?

Down 80% From Their Highs, Are These 2 Pandemic Darlings Bargain Buys?

Could this be the share-price catalyst that investors have been waiting for?

The FDA May Decide on Novavax's Vaccine Next Week: Here's What You Need to Know

The COVID-19 pandemic is still with us, but the effort to end it is starting a new chapter.

News for Novavax Stock (NVAX)